The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) is a huge mover today! About 323,943 shares traded hands or 10.37% up from the average. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 17.08% since March 9, 2016 and is downtrending. It has underperformed by 24.50% the S&P500.
The move comes after 7 months negative chart setup for the $125.06 million company. It was reported on Oct, 12 by Barchart.com. We have $3.06 PT which if reached, will make NASDAQ:TTPH worth $16.26M less.
Analysts await Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to report earnings on November, 7. They expect $-0.49 EPS, 0.00% or $0.00 from last year’s $-0.49 per share. After $-0.47 actual EPS reported by Tetraphase Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.26% negative EPS growth.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage
Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. On Wednesday, September 9 the stock rating was downgraded by JMP Securities to “Market Perform”. The firm has “Hold” rating given on Wednesday, September 9 by Stifel Nicolaus. The company was downgraded on Wednesday, September 9 by Needham. The rating was initiated by BMO Capital Markets with “Market Perform” on Tuesday, April 12. The firm has “Neutral” rating given on Wednesday, September 9 by Wedbush. Needham maintained Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) on Thursday, August 6 with “Buy” rating. The rating was downgraded by Gabelli on Friday, May 13 to “Neutral”. The firm has “Hold” rating given on Wednesday, September 9 by Cantor Fitzgerald. As per Wednesday, September 9, the company rating was downgraded by SunTrust. The stock has “Hold” rating given by Brean Capital on Wednesday, September 9.
According to Zacks Investment Research, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.31, from 1.17 in 2016Q1. The ratio worsened, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Teachers Advsrs Incorporated holds 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 58,899 shares. Moreover, Aqr Capital Mngmt has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 34,732 shares. Moreover, Morgan Stanley has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 24,279 shares. Invesco Limited accumulated 0% or 30,843 shares. Schwab Charles Invest Mngmt Incorporated holds 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 113,453 shares. Tudor Et Al accumulated 0% or 15,157 shares. Bridgeway Capital holds 361,717 shares or 0.02% of its portfolio. Joel Isaacson Commerce Lc holds 5,000 shares or 0% of its portfolio. Tekla Cap Mngmt Limited Liability last reported 192,322 shares in the company. Great Point Partners Lc reported 2.30 million shares or 2.83% of all its holdings. Manchester Capital Mgmt Ltd Com, a Vermont-based fund reported 7,492 shares. Victory Mngmt accumulated 633 shares or 0% of the stock. Vanguard Gru Inc has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Us Comml Bank De reported 500 shares or 0% of all its holdings. Federated Investors Inc Pa holds 93,303 shares or 0% of its portfolio.
More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Fool.com which released: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015, also Fool.com with their article: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” published on January 11, 2016, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on April 15, 2013. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Prnewswire.com and their article: “Hynes Keller & Hernandez, LLC Announces Investigation of Tetraphase …” published on June 23, 2016 as well as Globenewswire.com‘s news article titled: “Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a …” with publication date: August 01, 2016.
TTPH Company Profile
Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.